About 10 results found for searched term "51-65-0" (0.052 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2497 | Cathepsin Inhibitor 1 | Cathepsin |
| Cathepsin Inhibitor 1 is an inhibitor of Cathepsin (L, L2, S, K, B) with pIC50 of 7.9, 6.7, 6.0, 5.5 and 5.2, respectively. | ||
| M13486 | Enfuvirtide | Anti-infection |
| T20; DP178 | ||
| Enfuvirtide (T20; DP178) is an anti-HIV-1 fusion inhibitor peptide. | ||
| M14219 | NS11394 | GABA Receptor |
| NS11394 is an orally active and unique subtype-selective GABAA positive allosteric receptor (PAM), with a Ki of ~0.5 nM. | ||
| M25564 | Substance P (6-11) | Neurokinin Receptor |
| Substance P (6-11) is the C-terminal hexapeptideamide of Substance P. Substance P (6-11) binds to NK-1 tachykinin receptor. Substance P (6-11) shows depolarization of motoneurons and a hypotensive effect. | ||
| M30598 | Imeglimin | Mitochondrial Related |
| EMD 387008 | ||
| Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function. | ||
| M41247 | RSV L-protein-IN-1 | RSV |
| RSV L-protein-IN-1 is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). | ||
| M41249 | RSV L-protein-IN-4 | RSV |
| RSV L-protein-IN-4 is a noncompetitive RSV polymerase inhibitor (IC50: 0.88 μM). | ||
| M53044 | Substance P (5-11) | Neurokinin Receptor |
| Substance P (5-11), the C-terminal heptapeptide of Substance P (Substance P, is a neuropeptide. | ||
| M53761 | 2-Amino-3-(4-fluorophenyl)propanoic acid | Amino Acid Derivatives |
| 2-Amino-3-(4-fluorophenyl)propanoic acid is a phenylalanine derivative. | ||
| M54402 | Substance P (7-11) | Neurokinin Receptor |
| Substance P (7-11) is a C-terminal fragment of Substance P which can cause an increase in the intracellular calcium concentration. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
